Variations in Quinolinic Acid Levels in Tuberculosis Patients with Diabetes Comorbidity: A Pilot Prospective Cohort Study
Min Yang,Wenfei Wang,Peize Zhang,Guizhen Liu,Hailin Lu,Mingjie He,Guofang Deng,Xiaoyou Chen
DOI: https://doi.org/10.2147/idr.s465075
2024-07-13
Infection and Drug Resistance
Abstract:Min Yang, 1– 3, &ast Wenfei Wang, 3, &ast Peize Zhang, 4 Guizhen Liu, 5 Hailin Lu, 6 Mingjie He, 5 Guofang Deng, 2, 3 Xiaoyou Chen 1, 7 1 Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing, People's Republic of China; 2 Second Department of Pulmonary Medicine and Tuberculosis, the Third People's Hospital of Shenzhen, Southern University of Science and Technology, Shenzhen, Guangdong, People's Republic of China; 3 National Clinical Research Center for Infectious Disease, the Third People's Hospital of Shenzhen, Southern University of Science and Technology, Shenzhen, Guangdong, People's Republic of China; 4 Fourth Department of Pulmonary Medicine and Tuberculosis, the Third People's Hospital of Shenzhen, Southern University of Science and Technology, Shenzhen, Guangdong, People's Republic of China; 5 The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, People's Republic of China; 6 Gannan Medical University, Ganzhou, Jiangxi, People's Republic of China; 7 Infectious Diseases Department, Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiaoyou Chen; Guofang Deng, Email ; Objective: We aimed to investigate dysregulated metabolic pathways and identify diagnostic and therapeutic targets in patients with tuberculosis-diabetes (TB-DM). Methods: In our prospective cohort study, plasma samples were collected from healthy individuals, diabetic (DM) patients, untreated TB-only (TB-0)/TB-DM patients (TB-DM-0), and cured TB (TB-6)/TB-DM patients (TB-DM-6) to measure the levels of amino acids, fatty acids, and other metabolites in plasma using high-throughput targeted quantification methods. Results: Significantly different biological processes and biomarkers were identified in DM, TB-DM-0, and TB-DM-6 patients. Moreover, quinolinic acid (QA) showed excellent predictive accuracy for distinguishing between DM patients and TB-DM-0 patients, with an AUC of 1 (95% CI 1– 1). When differentiating between TB-DM-0 patients and TB-DM-6 patients, the AUC was 0.9297 (95% CI 0.8460– 1). Compared to those in DM patients, the QA levels were significantly elevated in TB-DM-0 patients and decreased significantly after antituberculosis treatment. We simultaneously compared healthy controls and untreated tuberculosis patients and detected an increase in the level of QA in the plasma of tuberculosis patients, which decreased following treatment. Conclusion: These findings improve the current understanding of tuberculosis treatment in patients with diabetes. QA may serve as an ideal diagnostic biomarker for TB-DM patients and contribute to the development of more effective treatments. Keywords: pulmonary tuberculosis, diabetes, metabolomics, quinolinic acid, biomarker TB is the second leading cause of death from a single infectious agent after coronavirus disease, and more than 10 million people continue to contract TB every year, making it a significant global public health issue. 1,2 Currently, there are approximately 463 million diabetes patients globally, and this number is projected to increase to 700 million by 2045. 3 In addition to increased susceptibility to active tuberculosis, diabetes worsens the severity of tuberculosis. 4 TB-DM patients are more likely to experience delayed sputum culture conversion, treatment failure, and higher rates of relapse, with relapse rates twice those of tuberculosis patients without diabetes. 5,6 Therefore, the dual burden of TB-DM represents a major global public health concern. Timely assessment of novel diagnostic and treatment strategies for TB-DM patients remains a global priority. 7 Tuberculosis bacillus culture or acid-fast bacilli smear microscopy, along with chest imaging, are currently the standard methods used to monitor the response to treatment. 8 Imaging techniques, such as X-ray and computed tomography (CT) scans, may not yield notable changes in the initial stages of treatment. Furthermore, the sputum acid-fast bacilli smear microscopy technique has a high false-negative rate of up to 50%. 9 The tuberculosis bacillus culture technique is time-consuming and has a low sensitivity of approximately 30%, rendering rapid assessment challenging. 10,11 Thus, there is a pressing need for more rapid, accurate methods to assess the diagnostic and therapeutic targets of tuberculosis, especially in di -Abstract Truncated-
pharmacology & pharmacy,infectious diseases